Independent research institute BioMed X has completed its oncology research project in partnership with Merck, the data from which has been acquired by Merck for further development, potentially leading to new therapeutic approaches in precision oncology. Launched in August 2022, the collaboration aimed to unravel the mechanisms behind the formation, propagation, and impact of ecDNA in cancer cells using single-cell screening and spatial technologies. The project was led by Dr. Alexandros Dra...